https://rijournals.com/biological-and-applied-science/

RESEARCH INVENTION JOURNAL OF BIOLOGICAL AND APPLIED SCIENCES 4(2):7-12, 2024

©RIJBAS Publications ISSN: 1597-2879

https://doi.org/10.59298/RIJBAS/2024/42712

Dendritic Cell Vaccines: Current Status and Future Prospects in Immunotherapy

Niwarinda Arnold

Faculty of Pharmacy Kampala International University Uganda

Email: arnold.niwarinda@studwc.kiu.ac.ug

ABSTRACT

Dendritic cell (DC) vaccines represent a promising advancement in cancer immunotherapy, capitalizing on the unique ability of dendritic cells to initiate and regulate immune responses by presenting antigens to T-cells. These vaccines work by isolating dendritic cells from a patient, loading them with tumor-associated antigens (TAAs), and reinfusing them to stimulate an immune response against cancer cells. The FDA approval of sipuleucel-T (Provenge) for metastatic prostate cancer in 2010 marked a significant milestone in the field, demonstrating the potential for DC vaccines to prolong survival in cancer patients. This review explores the mechanism of action of dendritic cell vaccines, focusing on the process of antigen loading, dendritic cell maturation, and T-cell activation. It also discusses current clinical applications, challenges such as antigen selection, tumor immune evasion, and the high complexity of vaccine production. Future prospects for DC vaccines include personalized cancer vaccines, improved antigen delivery methods, and combination therapies with immune checkpoint inhibitors to enhance effectiveness. Dendritic cell vaccines offer a novel and potentially durable approach to cancer treatment, but further research is needed to optimize their efficacy and broaden their application across various cancer types and other diseases.

Keywords: Dendritic cell vaccines, Cancer immunotherapy, Tumor-associated antigens (TAAs), T-cell activation, Combination therapies

INTRODUCTION

Dendritic cells (DCs) are pivotal players in the immune system, serving as the primary antigen-presenting cells (APCs) that bridge the innate and adaptive immune responses [1]. These specialized cells are responsible for capturing antigens from pathogens or tumor cells, processing them, and presenting them to T-cells, thereby initiating a robust and targeted immune response [2]. Dendritic cells not only activate cytotoxic T-lymphocytes (CTLs), which can directly kill infected or cancerous cells, but they also play a crucial role in regulating immune tolerance and preventing autoimmunity [3]. Given their unique ability to control the fate of the immune response, dendritic cells have become a focal point in cancer immunotherapy research. The idea of utilizing dendritic cells as vaccines for cancer therapy is based on their capacity to "educate" the immune system to recognize and eliminate cancer cells [4,5]. Unlike traditional cancer therapies such as chemotherapy or radiation, which aim to kill cancer cells directly, dendritic cell vaccines stimulate the patient's own immune system to target tumor cells [6]. This strategy is particularly appealing because it offers the potential for long-lasting protection through immunological memory, allowing the immune system to recognize and destroy cancer cells even after initial treatment [7]. This prospect of harnessing the body's natural defenses for durable cancer control has generated significant interest in the field of immunotherapy. The concept of dendritic cell vaccines originated from research conducted in the early 1990s, which demonstrated that dendritic cells could be cultured in vitro, loaded with tumor antigens, and used to stimulate T-cell responses against cancer [8]. This breakthrough provided the foundation for developing dendritic cell-based therapies for various types of cancer, including melanoma, prostate cancer, glioblastoma, and

renal cell carcinoma [9]. The first FDA-approved dendritic cell vaccine, sipuleucel-T (Provenge), marked a major milestone in 2010, setting the stage for further advancements in this innovative field. Sipuleucel-T is used to treat metastatic prostate cancer and demonstrated a significant survival benefit, highlighting the potential of dendritic cell vaccines to extend the lives of cancer patients [10]. Despite the promise of dendritic cell vaccines, several challenges remain in their clinical application. The production of these vaccines is complex, requiring the isolation and ex vivo manipulation of dendritic cells, followed by the introduction of tumor-associated antigens (TAAs) to train the immune system to recognize and attack cancer cells [11]. Tumor heterogeneity, immune evasion mechanisms, and the creation of immunosuppressive environments by tumors further complicate the effectiveness of dendritic cell vaccines in clinical settings [12]. Nonetheless, ongoing research is focused on overcoming these obstacles by improving antigen delivery methods, enhancing dendritic cell maturation, and combining DC vaccines with other immunotherapies to boost their efficacy. As cancer immunotherapy continues to evolve, dendritic cell vaccines are emerging as a promising therapeutic approach [13]. With advancements in personalized medicine, combination therapies, and novel antigen loading techniques, the future of DC vaccines looks bright. In this article, we will explore the current status of dendritic cell vaccines, their mechanisms of action, the challenges they face, and the future prospects of this cutting-edge approach to cancer treatment. By harnessing the full potential of dendritic cells, researchers hope to create more effective and durable treatments for cancer and other diseases [14].

The Role of Dendritic Cells in Immunity

Dendritic cells (DCs) play a central role in initiating and regulating immune responses, acting as a crucial link between the innate and adaptive immune systems. As professional antigen-presenting cells (APCs), dendritic cells are uniquely capable of capturing, processing, and presenting antigens to T-cells, thereby activating a targeted immune response [15]. They reside in peripheral tissues, including the skin, mucosal surfaces, and lymphoid organs, where they continuously sample the environment for pathogens, tumor antigens, or other foreign substances. Upon encountering antigens, dendritic cells undergo a process of maturation. During this maturation process, they upregulate key surface molecules, including major histocompatibility complex (MHC) class I and II molecules, as well as co-stimulatory molecules such as CD80 and CD86. These molecules are essential for effective T-cell activation. Immature dendritic cells are highly efficient at capturing antigens, while mature dendritic cells excel at presenting these antigens to T-cells [16]. Once matured, dendritic cells migrate to lymph nodes, where they present processed antigens to naïve T-cells. This antigen presentation initiates T-cell differentiation, leading to the activation of cytotoxic T-cells, which directly kill infected or cancerous cells, and helper T-cells, which support the overall immune response [17]. Dendritic cells also play a key role in maintaining immune tolerance, ensuring that the immune system does not overreact to self-antigens, thereby preventing autoimmune diseases. This dual ability to trigger immunity and regulate tolerance makes dendritic cells essential in immune defense and the development of immunotherapies, particularly in cancer treatment [18].

Mechanism of Dendritic Cell Vaccines

The mechanism of dendritic cell (DC) vaccines relies on the inherent ability of dendritic cells to activate T-cells and stimulate the immune system [19]. Dendritic cells are potent antigen-presenting cells (APCs) capable of capturing antigens from pathogens or tumors, processing them, and presenting them to T-cells, initiating both innate and adaptive immune responses. Dendritic cell vaccines take advantage of this natural process by using DCs to "teach" the immune system to recognize and attack cancer cells [20]. The process typically involves several critical steps:

1. Dendritic Cell Isolation and Generation

The first step in creating a dendritic cell vaccine is the isolation of dendritic cell precursors, usually obtained from the patient's blood. Monocytes or hematopoietic stem cells are typically used to generate dendritic cells in vitro [21]. These precursor cells are cultured in the presence of specific growth factors, such as granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4), to promote the differentiation and maturation of dendritic cells. This process yields immature dendritic cells, which are highly efficient at capturing antigens [22].

2. Antigen Loading

After generating immature dendritic cells, the next step is to load them with tumor-associated antigens (TAAs). These antigens can be derived from various sources, including tumor cell lysates, peptides, recombinant proteins, or even whole tumor RNA [23]. The type of antigen used is crucial, as it determines the specificity of the immune response. Once the dendritic cells capture these antigens, they process them and present them on their surface through major histocompatibility complex (MHC) molecules [24].

3. Dendritic Cell Maturation

For dendritic cells to effectively stimulate T-cells, they must undergo maturation. This is typically induced in vitro using factors such as toll-like receptor (TLR) agonists, cytokines, or other adjuvants. During maturation, dendritic cells upregulate the expression of MHC molecules and co-stimulatory molecules like CD80, CD86, and CD40 [25]. These co-stimulatory molecules are essential for the full activation of T-cells.

4. Reinfusion and T-Cell Activation

Once the dendritic cells are loaded with tumor antigens and fully matured, they are reinfused into the patient. After administration, the dendritic cells migrate to the lymph nodes, where they present the antigens to naïve T-cells. This interaction activates cytotoxic T-lymphocytes (CTLs), which can then seek out and destroy tumor cells expressing the specific antigens presented by the dendritic cells. Helper T-cells are also activated, aiding in the amplification and coordination of the immune response [16,26].

This multi-step process allows dendritic cell vaccines to trigger a targeted immune response against cancer, aiming to eliminate tumor cells and provide lasting immune surveillance through the generation of immunological memory.

Current Clinical Applications of Dendritic Cell Vaccines

Dendritic cell vaccines have been explored in the treatment of various cancers, including melanoma, prostate cancer, glioblastoma, and renal cell carcinoma. The most notable example of a dendritic cell vaccine is sipuleucel-T (Provenge), approved by the U.S. Food and Drug Administration (FDA) in 2010 for the treatment of metastatic prostate cancer. Sipuleucel-T demonstrated a significant survival benefit in patients with castration-resistant prostate cancer, marking a milestone in cancer immunotherapy [27,28].

Other dendritic cell vaccines, such as those targeting melanoma and glioblastoma, have shown promise in clinical trials, though their success has been variable [29]. In melanoma, dendritic cell vaccines have been combined with checkpoint inhibitors, such as anti-PD-1 and anti-CTLA-4 antibodies, to enhance the immune response [22]. Combination therapies are thought to overcome some of the challenges faced by DC vaccines in generating a sustained and robust immune response.

Additionally, DC vaccines have been investigated for their potential in treating hematological malignancies, including multiple myeloma and leukemia. The ability of dendritic cells to target specific tumor antigens offers hope for personalized cancer immunotherapy, where vaccines are tailored to the unique antigenic profile of a patient's tumor [30].

Challenges and Limitations of Dendritic Cell Vaccines

Despite their promise, dendritic cell vaccines face several challenges that limit their widespread clinical use. One of the key challenges is the **complexity of vaccine production**. The process of isolating dendritic cells, loading them with antigens, and ensuring their proper maturation is labor-intensive and costly. The need for personalized vaccine preparation for each patient adds to the complexity and cost of treatment [31].

Antigen selection is another challenge. The choice of tumor-associated antigens is critical for generating an effective immune response. However, tumors are highly heterogeneous, and selecting antigens that are universally expressed across tumor cells can be difficult. Moreover, tumors can evade immune detection by downregulating the expression of targeted antigens, making it harder for dendritic cells to activate a robust immune response [32]. Immune evasion mechanisms employed by tumors also present a significant barrier. Tumors can create an immunosuppressive microenvironment by secreting factors that inhibit the activity of dendritic cells and T-cells. They may also express immune checkpoint molecules, such as PD-L1, which suppress the immune response. Combining DC vaccines with checkpoint inhibitors and other immunomodulatory agents is a promising strategy to overcome this challenge [33]. Additionally, the efficacy of dendritic cell vaccines has been variable across clinical trials. While some patients show durable responses and prolonged survival, others do not respond as effectively. Factors such as the tumor type, stage of the disease, and the patient's overall immune status can influence the success of DC vaccination [30].

Future Prospects in Dendritic Cell Vaccines

The future of dendritic cell vaccines in immunotherapy looks promising, with several advancements underway that may address current challenges and improve their efficacy. Some of the most exciting future prospects include:

a) **Personalized Cancer Vaccines:** Advances in genomic and proteomic technologies have made it possible to identify neoantigens—unique mutations in a patient's tumor [34]. These neoantigens can be used to create personalized dendritic cell vaccines tailored to each patient's specific tumor profile. Personalized vaccines have the potential to generate highly specific immune responses that target the unique mutations in the tumor, improving treatment outcomes.

b) **Combination Therapies:** Combining dendritic cell vaccines with other immunotherapies, such as checkpoint inhibitors (e.g., anti-PD-1, anti-CTLA-4) and cytokine therapies, can enhance the immune response by overcoming the tumor's immunosuppressive mechanisms. Combination therapies may help boost the efficacy of dendritic cell vaccines and result in more durable responses [35].

c) **Improved Antigen Delivery:** Novel methods of antigen delivery, such as RNA-based vaccines, nanoparticles, and exosomes, are being explored to enhance the effectiveness of dendritic cell vaccines. These technologies allow for more efficient loading of antigens onto dendritic cells and may improve the targeting and activation of T-cells [36].

d) **Allogeneic Dendritic Cell Vaccines:** Researchers are investigating the use of allogeneic (donor-derived) dendritic cells, which could offer a more standardized and scalable approach to vaccine production. Allogeneic dendritic cells can be preloaded with antigens and administered to multiple patients, reducing the complexity and cost associated with personalized vaccine production [37,38].

e) **Enhancing Dendritic Cell Maturation:** Research is ongoing to identify optimal strategies for maturing dendritic cells, ensuring that they can effectively activate T-cells and generate a potent immune response. Toll-like receptor (TLR) agonists, cytokines, and adjuvants are being studied as potential agents to enhance dendritic cell function and improve the efficacy of DC vaccines [39,40].

CONCLUSION

Dendritic cell vaccines represent a novel and promising approach to cancer immunotherapy. By harnessing the unique ability of dendritic cells to activate T-cells and elicit a robust immune response, these vaccines offer a potential strategy for treating a wide range of cancers. While challenges such as production complexity, antigen selection, and tumor immune evasion remain, advances in personalized medicine, combination therapies, and novel antigen delivery methods hold great promise for improving the efficacy of dendritic cell vaccines. As research progresses, dendritic cell vaccines may become an integral part of the immunotherapy landscape, offering new hope for cancer patients and paving the way for innovative treatments in the fight against cancer.

REFERENCES

1. Boscardin SB, Dudziak D, Münz C, Rosa DS. Editorial: Harnessing the Participation of Dendritic Cells in Immunity and Tolerance. Front Immunol. 2020 Oct 7;11:595841. doi: 10.3389/fimmu.2020.595841. PMID: 33117409; PMCID: PMC7575758.
2. Liu K. Dendritic Cells. Encyclopedia of Cell Biology. 2016:741–9. doi: 10.1016/B978-0-12-394447-4.30111-0. Epub 2015 Aug 20. PMCID: PMC7148618.
3. Xing Li, Yanping Han, Erwei Sun, Sniping the scout: Targeting the key molecules in dendritic cell functions for treatment of autoimmune diseases, Pharmacological Research, 2016; 107, 27-41, https://doi.org/10.1016/j.phrs.2016.02.023.
4. Troise D, Infante B, Mercuri S, Catalano V, Ranieri E, Stallone G. Dendritic Cells: A Bridge between Tolerance Induction and Cancer Development in Transplantation Setting. *Biomedicines*. 2024; 12(6):1240. https://doi.org/10.3390/biomedicines12061240
5. Lizhe Sun, Xianwei Wang, Jason Saredy, Zuyi Yuan, Xiaofeng Yang, Hong Wang, Innate-adaptive immunity interplay and redox regulation in immune response, Redox Biology, 2020; 37,101759. https://doi.org/10.1016/j.redox.2020.101759.
6. Liu D, Che X, Wang X, Ma C, Wu G. Tumor Vaccines: Unleashing the Power of the Immune System to Fight Cancer. Pharmaceuticals (Basel). 2023 Sep 29;16(10):1384. doi: 10.3390/ph16101384. PMID: 37895855; PMCID: PMC10610367.
7. Saxena M, Bhardwaj N. Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment. Trends Cancer. 2018 Feb;4(2):119-137. doi: 10.1016/j.trecan.2017.12.007. PMID: 29458962; PMCID: PMC5823288.
8. Sajad Najafi, Keywan Mortezaee, Advances in dendritic cell vaccination therapy of cancer, Biomedicine & Pharmacotherapy, 2023; 164, 114954. https://doi.org/10.1016/j.biopha.2023.114954.
9. Sabado, R., Balan, S. & Bhardwaj, N. Dendritic cell-based immunotherapy. *Cell Res* **27**, 74–95 (2017). https://doi.org/10.1038/cr.2016.157
10. Hato L, Vizcay A, Eguren I, Pérez-Gracia JL, Rodríguez J, Gállego Pérez-Larraya J, Sarobe P, Inogés S, Díaz de Cerio AL, Santisteban M. Dendritic Cells in Cancer Immunology and Immunotherapy. *Cancers*. 2024; 16(5):981. https://doi.org/10.3390/cancers16050981
11. Kim SK, Cho SW. The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment. Front Pharmacol. 2022 May 24;13:868695. doi: 10.3389/fphar.2022.868695. PMID: 35685630; PMCID: PMC9171538.

12. Tie Y, Tang F, Wei YQ, Wei XW. Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets. J Hematol Oncol. 2022 May 18;15(1):61. doi: 10.1186/s13045-022-01282-8. PMID: 35585567; PMCID: PMC9118588.
13. Ishita Gupta, Ola Hussein, Konduru Seetharama Sastry, Salim Bougarn, Neha Gopinath, Evonne Chin-Smith, Yashi Sinha, Hesham Mohamed Korashy, Cristina Maccalli, Deciphering the complexities of cancer cell immune evasion: Mechanisms and therapeutic implications, Advances in Cancer Biology - Metastasis, 2023; 8, 100107. https://doi.org/10.1016/j.adcanc.2023.100107.
14. Chen, K., Shuen, T.W.H. & Chow, P.K.H. The association between tumour heterogeneity and immune evasion mechanisms in hepatocellular carcinoma and its clinical implications. *Br J Cancer* **131**, 420–429 (2024). https://doi.org/10.1038/s41416-024-02684-w
15. Tie, Y., Tang, F., Wei, Yq. *et al.* Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets. *J Hematol Oncol* **15**, 61 (2022). https://doi.org/10.1186/s13045-022-01282-8
16. Liu D, Che X, Wang X, Ma C, Wu G. Tumor Vaccines: Unleashing the Power of the Immune System to Fight Cancer. *Pharmaceuticals*. 2023; 16(10):1384. https://doi.org/10.3390/ph16101384
17. 17 Jia, Q., Wang, A., Yuan, Y. *et al.* Heterogeneity of the tumor immune microenvironment and its clinical relevance. *Exp Hematol Oncol* **11**, 24 (2022). https://doi.org/10.1186/s40164-022-00277-y
18. Saadeldin MK, Abdel-Aziz AK, Abdellatif A. Dendritic cell vaccine immunotherapy; the beginning of the end of cancer and COVID-19. A hypothesis. Med Hypotheses. 2021 Jan;146:110365. doi: 10.1016/j.mehy.2020.110365. Epub 2020 Nov 9. PMID: 33221134; PMCID: PMC7836805.
19. Macri C, Dumont C, Johnston AP, Mintern JD. Targeting dendritic cells: a promising strategy to improve vaccine effectiveness. Clin Transl Immunology. 2016 Mar 18;5(3):e66. doi: 10.1038/cti.2016.6. PMID: 27217957; PMCID: PMC4815026.
20. Waldman, A.D., Fritz, J.M. & Lenardo, M.J. A guide to cancer immunotherapy: from T cell basic science to clinical practice. *Nat Rev Immunol* **20**, 651–668 (2020). https://doi.org/10.1038/s41577-020-0306-5
21. Kurilin V, Alshevskaya A, Sennikov S. Development of Cell Technologies Based on Dendritic Cells for Immunotherapy of Oncological Diseases. *Biomedicines*. 2024; 12(3):699. https://doi.org/10.3390/biomedicines12030699
22. Soloff, A., Barratt-Boyes, S. Enemy at the gates: dendritic cells and immunity to mucosal pathogens. *Cell Res* **20**, 872–885 (2010). https://doi.org/10.1038/cr.2010.94
23. González FE, Gleisner A, Falcón-Beas F, Osorio F, López MN, Salazar-Onfray F. Tumor cell lysates as immunogenic sources for cancer vaccine design. Hum Vaccin Immunother. 2014;10(11):3261-9. doi: 10.4161/21645515.2014.982996. PMID: 25625929; PMCID: PMC4514089.
24. Feola S, Chiaro J, Martins B, Cerullo V. Uncovering the Tumor Antigen Landscape: What to Know about the Discovery Process. Cancers (Basel). 2020 Jun 23;12(6):1660. doi: 10.3390/cancers12061660. PMID: 32585818; PMCID: PMC7352969.
25. Xie, N., Shen, G., Gao, W. *et al.* Neoantigens: promising targets for cancer therapy. *Sig Transduct Target Ther* **8**, 9 (2023). https://doi.org/10.1038/s41392-022-01270-x
26. Joyce, S. (2023). Cancer Antigens: Sources, Generation, and Presentation. In: Rezaei, N. (eds) Handbook of Cancer and Immunology. Springer, Cham. https://doi.org/10.1007/978-3-030-80962-1_38-1
27. Lin, M.J., Svensson-Arvelund, J., Lubitz, G.S. *et al.* Cancer vaccines: the next immunotherapy frontier. *Nat Cancer* **3**, 911–926 (2022). https://doi.org/10.1038/s43018-022-00418-6
28. Chiang CL-L, Coukos G, Kandalaft LE. Whole Tumor Antigen Vaccines: Where Are We? *Vaccines*. 2015; 3(2):344-372. https://doi.org/10.3390/vaccines3020344
29. Subtirelu RC, Teichner EM, Ashok A, Parikh C, Talasila S, Matache IM, Alnemri AG, Anderson V, Shahid O, Mannam S, Lee A, Werner T, Revheim ME, Alavi A. Advancements in dendritic cell vaccination: enhancing efficacy and optimizing combinatorial strategies for the treatment of glioblastoma. Front Neurol. 2023 Oct 31;14:1271822. doi: 10.3389/fneur.2023.1271822. PMID: 38020665; PMCID: PMC10644823.
30. Schaller TH, Sampson JH. Advances and challenges: dendritic cell vaccination strategies for glioblastoma. Expert Rev Vaccines. 2017 Jan;16(1):27-36. doi: 10.1080/14760584.2016.1218762. Epub 2016 Aug 10. PMID: 27500911; PMCID: PMC5479410.
31. Zujian Xiong, Itay Raphael, Michael Olin, Hideho Okada, Xuejun Li, Gary Kohanbash, Glioblastoma vaccines: past, present, and opportunities, eBioMedicine, 2024; 100,104963. https://doi.org/10.1016/j.ebiom.2023.104963.

32. Fan, T., Zhang, M., Yang, J. *et al.* Therapeutic cancer vaccines: advancements, challenges and prospects. *Sig Transduct Target Ther* **8**, 450 (2023). https://doi.org/10.1038/s41392-023-01674-3
33. Kaczmarek M, Poznańska J, Fechner F, Michalska N, Paszkowska S, Napierała A, Mackiewicz A. Cancer Vaccine Therapeutics: Limitations and Effectiveness—A Literature Review. *Cells.* 2023; 12(17):2159. https://doi.org/10.3390/cells12172159
34. Bausart, M., Préat, V. & Malfanti, A. Immunotherapy for glioblastoma: the promise of combination strategies. *J Exp Clin Cancer Res* **41**, 35 (2022). https://doi.org/10.1186/s13046-022-02251-2
35. Li X, You J, Hong L, Liu W, Guo P, Hao X. Neoantigen cancer vaccines: a new star on the horizon. Cancer Biol Med. 2023 Dec 29;21(4):274–311. doi: 10.20892/j.issn.2095-3941.2023.0395. PMID: 38164734; PMCID: PMC11033713.
36. Blass E, Ott PA. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol. 2021 Apr;18(4):215-229. doi: 10.1038/s41571-020-00460-2. Epub 2021 Jan 20. PMID: 33473220; PMCID: PMC7816749.
37. Himuro, H., Sasada, T. (2022). Personalized Cancer Vaccines Targeting Neoantigens. In: Rezaei, N. (eds) Handbook of Cancer and Immunology. Springer, Cham. https://doi.org/10.1007/978-3-030-80962-1_291-1
38. Zhang T, Kurban E, Wang Z. Neoantigens: The Novel Precision Cancer Immunotherapy. *Biologics.* 2023; 3(4):321-334. https://doi.org/10.3390/biologics3040017
39. Chiranjib Chakraborty, Anirban Majumder, Manojit Bhattacharya, Srijan Chatterjee, Sang-Soo Lee, The landscape of neoantigens and its clinical applications: From immunobiology to cancer vaccines, Current Research in Biotechnology, 2024; 7,100177. https://doi.org/10.1016/j.crbiot.2024.100177.
40. Chi, WY., Hu, Y., Huang, HC. *et al.* Molecular targets and strategies in the development of nucleic acid cancer vaccines: from shared to personalized antigens. *J Biomed Sci* **31**, 94 (2024). https://doi.org/10.1186/s12929-024-01082-x

CITE AS: Niwarinda Arnold. (2024). Dendritic Cell Vaccines: Current Status and Future Prospects in Immunotherapy. RESEARCH INVENTION JOURNAL OF BIOLOGICAL AND APPLIED SCIENCES 4(2):7-12. https://doi.org/10.59298/RIJBAS/2024/42712